XML 50 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
OTHER EXPENSE (INCOME)
 12 Months Ended
Dec. 31, 2016
Other Income and Expenses [Abstract]  
OTHER EXPENSES (INCOME)
OTHER EXPENSE (INCOME)
Other expense (income) for the years ended December 31, 2016, 2015 and 2014 were as follows:
(in millions)
 
2016
 
2015
 
2014
(Gain) loss on sale of assets
 
$
(6
)
 
$
8

 
$
(251
)
Other post business combination expenses
 
—

 
183

 
27

Acquisition-related costs
 
2

 
39

 
6

Loss (gain) on litigation settlements
 
59

 
37

 
(45
)
Other, net
 
18

 
28

 
—

Other expense (income)
 
$
73

 
$
295

 
$
(263
)
Other expense, net was $73 million for 2016. Loss on litigation settlements includes (i) an unfavorable adjustment of $90 million from the proposed settlement of the Salix securities litigation and (ii) a favorable adjustment of $39 million from the settlement of the investigation into Salix's pre-acquisition sales and promotional practices for the Xifaxan®, Relistor® and Apriso® products. Gain on sales of assets includes (i) a gain of $20 million from an amendment to a license agreement terminating the Company's right to develop and commercialize brodalumab in Europe and (ii) a loss of $22 million from the divestiture of Ruconest®.
Other expense, net was $295 million for 2015. Other post business combination expenses includes (i) $168 million related to the acceleration of unvested restricted stock for Salix employees (including $3 million of related payroll taxes) in connection with the Salix Acquisition and (ii) $12 million related to bonuses paid to Amoun employees. Loss on litigation settlements includes $25 million related to the AntiGrippin® litigation.
Other income, net was $263 million for 2014. Gain on sales of assets includes (i) $324 million related to the divestiture of facial aesthetic fillers and toxins and (ii) losses of $59 million related to the divestiture of Metronidazole 1.3% and $9 million related to the divestiture of the generic tretinoin product rights, acquired in the PreCision Acquisition. Gain on litigation settlements includes a favorable adjustment of $50 million related to the AntiGrippin® litigation. Other post business combination expenses include $20 million related to the acceleration of unvested stock options for certain PreCision employees.